Lunai Bioworks, Inc., formerly Renovaro Inc., is focused on AI-powered biodefense, drug discovery and advanced diagnostics. The Company is engaged in harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform. These are designed to transform clinical decision-making, reduce time-to-treatment, and unlock previously inaccessible insights from biological data. Its proprietary platforms in translational analytics, in vivo modeling, and machine vision-accelerating biomarker discovery and therapeutic development in precision neurology and infectious disease.
企業コードRENB
会社名Lunai Bioworks Inc
上場日Nov 18, 2014
最高経営責任者「CEO」Weinstein (David)
従業員数- -
証券種類Ordinary Share
決算期末Nov 18
本社所在地2080 Century Park East, Suite 906
都市LOS ANGELES
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号90067
電話番号14539179840
ウェブサイト
企業コードRENB
上場日Nov 18, 2014
最高経営責任者「CEO」Weinstein (David)
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし